Clinical Trials on Blood Protein Disorders

Total 201698 results

Emory University
Takeda Pharmaceuticals North America, Inc.

Recruiting

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (SAFE)

Hemophilia A

United States
Washington Institute for Coagulation
Genentech, Inc.

Recruiting

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A (EmiMSK)

Hemophilia A

United States
Emory University
Octapharma

Recruiting

Treatment of Hemophilia A Patients With FVIII Inhibitors (MOTIVATE)

Hemophilia A

United States, Germany
Sinocelltech Ltd.

Recruiting

Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

Hemophilia A

China
Medical College of Wisconsin

Recruiting

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

Hemophilia A

United States
Takeda

Completed

A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions

Hemophilia

France
Bayer

Active, not recruiting

Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study) (LIFE-ACTIVE)

Hemophilia A

Canada, Spain, United States, Belgium, Italy, Taiwan, Slovenia
Hoffmann-La Roche

Active, not recruiting

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants (HAVEN 5)

Hemophilia A

China, Thailand, Hong Kong, Malaysia
Bioverativ, a Sanofi company

Active, not recruiting

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A (XTEND-ed)

Hemophilia A

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom
Genzyme, a Sanofi Company

Active, not recruiting

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX (ATLAS-OLE)

Hemophilia

China, Hungary, Turkey, Canada, Korea, Republic of, United States, Australia, Denmark, France, Germany, India, Ireland, Israel, Italy, Japan, Malaysia, South Africa, Taiwan, Ukraine, United Kingdom
Haemnet
BioMarin Pharmaceutical

Completed

Learning to Live With Non-severe Haemophilia

Hemophilia

United Kingdom
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

A Study of ADVATE in People With Hemophilia A in India

Hemophilia A

India
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
Hospices Civils de Lyon

Completed

Satisfaction Regarding the Dispensing of Emicizumab (HEMLIBRA®) for Patients With Haemophilia A in France (PASODOBLEDEMI2)

Hemophilia A

France
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Physical Activity and FVIII Elimination: Relevance to Personalized Therapy in Severe Hemophilia A

Hemophilia A

Italy
Swedish Orphan Biovitrum
ICON plc

Completed

Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products

Hemophilia A

France, Italy, Norway, Sweden, United Kingdom, Austria, Belgium, Finland, Spain
Genzyme, a Sanofi Company

Completed

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis (ATLAS-PPX)

Hemophilia

United States, Australia, China, Denmark, France, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Turkey, Ukraine, United Kingdom, Mexico
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4)

Hemophilia A

United States, Belgium, Spain, Japan, Poland, Australia
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)

Hemophilia A

Australia, Taiwan, Korea, Republic of, France, Germany, Italy, South Africa, Spain, United States, Japan, Ireland, Poland, United Kingdom, Costa Rica
Istanbul University - Cerrahpasa (IUC)

Completed

The Effects of Exercise Training in Children With Hemophilia

Hemophilia

Turkey
Grifols Therapeutics LLC
Instituto Grifols, S.A.

Completed

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia (IG0902)

Congenital Afibrinogenemia

India, United States, Italy, Lebanon
Octapharma

Completed

Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

Hemophilia A

Norway, United States, France, United Kingdom, Italy, Czechia, Argentina, Belarus, Ecuador, Guatemala, Lithuania, Portugal, Slovakia
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

BAX 802 in CHA With Inhibitors (CHAWI)

Hemophilia A

Netherlands, Spain, Italy, Turkey, Bulgaria, United States, Canada, Germany, Norway, Poland, Russian Federation, South Africa
Baxalta now part of Shire

Completed

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

Hemophilia A

United States
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Baxalta now part of Shire

Completed

BAX 855 Pediatric Study

Hemophilia A

United States, Spain, United Kingdom, Taiwan, Malaysia, Bulgaria, Hong Kong, Korea, Republic of, Netherlands, Turkey, Ukraine
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Hemophilia A

United States, Belgium, France, Norway, Netherlands, Austria, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Spain, Sweden
Baxalta now part of Shire

Terminated

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

Hemophilia

United Kingdom
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Hemophilia A

United States, Canada, Puerto Rico
Lund University

Completed

Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A (myPKFiT)

Hemophilia A

Sweden
Baxalta now part of Shire

Completed

GAS-Hem Feasibility Study

Hemophilia A

Canada, United States
AryoGen Pharmed Co.

Completed

Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency

Factor VII Deficiency

Iran, Islamic Republic of
Delta University for Science and Technology

Unknown

Pulsed Electromagentic Field in Haemophilia

Hemophilia A

Egypt
Victor Blanchette
Queen's University; Sydney Children's Hospitals Network; Royal Children's Hospital and other collaborators

Unknown

Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia

Hemophilia A
Kaifeng Pharmaceutical (Group) Co., Ltd.
Beijing Furen Biomedical Research Institute Co., Ltd.

Unknown

A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Hemophilia A

China
Nationwide Children's Hospital
The Hospital for Sick Children

Completed

Exercise Versus DDAVP in Patients With Mild Hemophilia A

Hemophilia A

United States
Octapharma

Completed

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Germany, Bulgaria
Bayer

Completed

BAY94-9027 PK Study Comparing to Another Long Acting Product

Hemophilia A

Bulgaria
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China
FH Campus Wien, University of Applied Sciences
Medical University of Vienna; Shire

Completed

Gait Examination in Patients With Hemophilia in Austria (JOSEPHA)

Hemophilia

Austria
Pfizer

Completed

Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting

Hemophilia A

Spain, France, Turkey, Netherlands, Germany, Italy, Ukraine
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FVIII Gene Therapy

Hemophilia A

China
Pfizer

Completed

Study Evaluating Pharmacovigilance Of Refacto AF

Hemophilia A

Germany, Austria
University Hospital, Brest

Completed

Health Practice of Hemophilia Patiente Care During Pregnancy, Delivery and Newborn Children (ECHANGE)

Hemophilia

France
Fondazione Angelo Bianchi Bonomi
Sintesi Research Srl

Completed

Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET)

Hemophilia A

United States, India, Spain, Argentina, Austria, Brazil, Chile, Egypt, Iran, Islamic Republic of, Italy, Mexico, Saudi Arabia, South Africa, Turkey
CSL Behring
Parexel

Completed

Study of Biostate® in Children With Hemophilia A

Hemophilia A

Ukraine, Lebanon, Belarus, Georgia, Guatemala, Mexico
Pfizer

Completed

PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

Hemophilia A

China
University Hospital, Toulouse

Completed

Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study. (END-HEMO)

Hemophilia A

France
Pfizer

Completed

Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients

Hemophilia A

Spain, Finland, Serbia, Georgia, Italy, Romania, Sweden, Turkey, Ukraine

Clinical Trials on Blood Protein Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations